23 results on '"Schoots, I.G. (Ivo)"'
Search Results
2. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.016: Prebiopsy MRI: Through the Looking Glass
- Author
-
Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), Willemse, P.-P.M. (Peter-Paul M.), Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), and Willemse, P.-P.M. (Peter-Paul M.)
- Published
- 2020
- Full Text
- View/download PDF
3. Equivocal pi-rads three lesions on prostate magnetic resonance imaging: Risk stratification strategies to avoid mri-targeted biopsies
- Author
-
Osses, D.F. (Daniël), Arsov, C. (Christian), Schimmöller, L. (Lars), Schoots, I.G. (Ivo), Leenders, G.J.H.L. (Geert), Esposito, I. (I.), Remmers, S. (Sebastiaan), Albers, P. (Peter), Roobol-Bouts, M.J. (Monique), Osses, D.F. (Daniël), Arsov, C. (Christian), Schimmöller, L. (Lars), Schoots, I.G. (Ivo), Leenders, G.J.H.L. (Geert), Esposito, I. (I.), Remmers, S. (Sebastiaan), Albers, P. (Peter), and Roobol-Bouts, M.J. (Monique)
- Abstract
We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging—Reporting and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013–2019) from two referral centers were included. A multivariable logistic regression analysis was performed. The discrimination and clinical utility of the built model was assessed by the area under the receiver operation curve (AUC) and decision curve analysis, respectively. A higher PSA-D and higher age were significantly related to a higher risk of detecting csPCa, while the largest index lesion diameter was not. The discrimination of the model was 0.80 (95% CI 0.73–0.87). When compared to a biopsy-all strategy, decision curve analysis showed a higher net benefit at threshold probabilities of ≥2%. Accepting a missing ≤5% of csPCa diagnoses, a risk-based approach would result in 34% of TBx sessions and 23% of low-risk PCa diagnoses being avoided. In men with PI-RADS 3 index lesions scheduled for first-time TBx, the balance between the number of TBx sessions, the detection of low-risk PCa, and the detection of csPCa does not warrant a biopsy-all strategy. To minimize the risk of missing the diagnosis of csPCa but acknowledging the need of avoiding unnecessary TBx sessions and overdiagnosis, a risk-based approach is advisable.
- Published
- 2020
- Full Text
- View/download PDF
4. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis
- Author
-
Drost, F.J.H. (Frank-Jan), Osses, D.F. (Daniël), Nieboer, D. (Daan), Bangma, C.H. (Chris), Steyerberg, E.W. (Ewout), Roobol-Bouts, M.J. (Monique), Schoots, I.G. (Ivo), Drost, F.J.H. (Frank-Jan), Osses, D.F. (Daniël), Nieboer, D. (Daan), Bangma, C.H. (Chris), Steyerberg, E.W. (Ewout), Roobol-Bouts, M.J. (Monique), and Schoots, I.G. (Ivo)
- Abstract
Context: Magnetic resonance imaging (MRI), with or without MRI-targeted biopsy (MRI pathway), is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision making. Objective: To determine the diagnostic accuracy of the index t
- Published
- 2020
- Full Text
- View/download PDF
5. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
- Author
-
Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J., Evans, AJ, Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G., McKenney, JK, Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P., Samaratunga, H, Schoots, I.G. (Ivo), Simko, J.P., Tsuzuki, T., Varma, M, Warren, AY, Wheeler, T.M. (Thomas), Williamson, S.R., Iczkowski, KA, Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J., Evans, AJ, Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G., McKenney, JK, Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P., Samaratunga, H, Schoots, I.G. (Ivo), Simko, J.P., Tsuzuki, T., Varma, M, Warren, AY, Wheeler, T.M. (Thomas), Williamson, S.R., and Iczkowski, KA
- Abstract
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging–targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.
- Published
- 2020
- Full Text
- View/download PDF
6. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
- Author
-
Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J. (David J.), Evans, A.J. (Andrew J.), Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G. (Geert), McKenney, J.K. (Jesse K.), Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P. (Gladell P.), Samaratunga, H. (Hemamali), Schoots, I.G. (Ivo), Simko, J. (Jeff), Tsuzuki, T. (Toyonori), Varma, M. (Murali), Warren, A.Y. (Anne Y.), Wheeler, T.M. (Thomas), Williamson, S.R. (Sean R.), Iczkowski, K.A. (Kenneth A.), Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J. (David J.), Evans, A.J. (Andrew J.), Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G. (Geert), McKenney, J.K. (Jesse K.), Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P. (Gladell P.), Samaratunga, H. (Hemamali), Schoots, I.G. (Ivo), Simko, J. (Jeff), Tsuzuki, T. (Toyonori), Varma, M. (Murali), Warren, A.Y. (Anne Y.), Wheeler, T.M. (Thomas), Williamson, S.R. (Sean R.), and Iczkowski, K.A. (Kenneth A.)
- Abstract
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging-targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.
- Published
- 2020
- Full Text
- View/download PDF
7. Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists’ Training
- Author
-
Rooij, M. (Maarten) de, Israël, B. (Bas), Barrett, T. (Tristan), Giganti, F. (Francesco), Padhani, A. (Anwar), Panebianco, V. (Valeria), Richenberg, J. (Jonathan), Salomon, G. (Georg), Schoots, I.G. (Ivo), Villeirs, G. (Geert), Walz, J. (Jochen), Barentsz, J. (Jelle), Rooij, M. (Maarten) de, Israël, B. (Bas), Barrett, T. (Tristan), Giganti, F. (Francesco), Padhani, A. (Anwar), Panebianco, V. (Valeria), Richenberg, J. (Jonathan), Salomon, G. (Georg), Schoots, I.G. (Ivo), Villeirs, G. (Geert), Walz, J. (Jochen), and Barentsz, J. (Jelle)
- Abstract
Objectives This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prerequisites for image quality. Methods A total of 44 leading urologists and urogenital radiologists who are experts in prostate cancer imaging from the European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI) participated in a Delphi consensus process. Panellists completed two rounds of questionnaires with 55 items under three headings: image quality assessment, interpretation and reporting, and radiologists’ experience plus training centres. Of 55 questions, 31 were rated for agreement on a 9-point scale, and 24 were multiple-choice or open. For agreement items, there was consensus agreement with an agreement ≥ 70% (score 7–9) and disagreement of ≤ 15% of the panellists. For the other questions, a consensus was considered with ≥ 50% of votes. Results Twenty-four out of 31 of agreement items and 11/16 of other questions reached consensus. Agreement statements were (1) reporting of image quality should be performed and implemented into clinical practice; (2) for interpretation performance, radiologists should use self-performance tests with histopathology feedback, compare their interpretation with expert-reading and use external performance assessments; and (3) radiologists must attend theoretical and hands-on courses before interpreting prostate MRI. Limitations are that the results are expert opinions and not based on systematic reviews or meta-analyses. There was no consensus on outco
- Published
- 2020
- Full Text
- View/download PDF
8. Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI
- Author
-
Arif, M. (Muhammad), Schoots, I.G. (Ivo), Castillo Tovar, J. (Jose), Bangma, C.H. (Chris), Krestin, G.P. (Gabriel), Roobol-Bouts, M.J. (Monique), Niessen, W.J. (Wiro), Veenland, J.F. (Jifke), Arif, M. (Muhammad), Schoots, I.G. (Ivo), Castillo Tovar, J. (Jose), Bangma, C.H. (Chris), Krestin, G.P. (Gabriel), Roobol-Bouts, M.J. (Monique), Niessen, W.J. (Wiro), and Veenland, J.F. (Jifke)
- Abstract
Objectives: To develop an automatic method for identification and segmentation of clinically significant prostate cancer in low-risk patients and to evaluate the performance in a routine clinical setting. Methods: A consecutive cohort (n = 292) from a prospective database of low-risk patients eligible for the active surveillance was selected. A 3-T multi-parametric MRI at 3 months after inclusion was performed. Histopathology from biopsies was used as reference standard. MRI positivity was defined as PI-RADS score ≥ 3, histopathology positivity was defined as ISUP grade ≥ 2. The selected cohort contained four patient groups: (1) MRI-positive targeted biopsy-positive (n = 116), (2) MRI-negative systematic biopsy-negative (n = 55), (3) MRI-positive targeted biopsy-negative (n = 113), (4) MRI-negative systematic biopsy-positive (n = 8). Group 1 was further divided into three sets and a 3D convolutional neural network was trained using different combinations of these sets. Two MRI sequences (T2w, b = 800 DWI) and the ADC map were used as separate input channels for the model. After training, the model was evaluated on the remaining group 1 patients together with the patients of groups 2 and 3 to identify and segment clinically significant prostate cancer. Results: The average sensitivity achieved was 82–92% at an average specificity of 43–76% with an area under the curve (AUC) of 0.65 to 0.89 for different lesion volumes ranging from >
- Published
- 2020
- Full Text
- View/download PDF
9. Automated classification of significant prostate cancer on MRI: A systematic review on the performance of machine learning applications
- Author
-
Castillo, J.M.T. (Jose M. T.), Arif, M. (Muhammad), Niessen, W.J. (Wiro), Schoots, I.G. (Ivo), Veenland, J.F. (Jifke), Castillo, J.M.T. (Jose M. T.), Arif, M. (Muhammad), Niessen, W.J. (Wiro), Schoots, I.G. (Ivo), and Veenland, J.F. (Jifke)
- Abstract
Significant prostate carcinoma (sPCa) classification based on MRI using radiomics or deep learning approaches has gained much interest, due to the potential application in assisting in clinical decision-making. Objective: To systematically review the literature (i) to determine which algorithms are most frequently used for sPCa classification, (ii) to investigate whether there exists a relation between the performance and the method or the MRI sequences used, (iii) to assess what study design factors affect the performance on sPCa classification, and (iv) to research whether performance had been evaluated in a clinical setting Methods: The databases Embase and Ovid MEDLINE were searched for studies describing machine learning or deep learning classification methods discriminating between significant and nonsignificant PCa on multiparametric MRI that performed a valid validation procedure. Quality was assessed by the modified radiomics quality score. We computed the median area under the receiver operating curve (AUC) from overall methods and the interquartile range. Results: From 2846 potentially relevant publications, 27 were included. The most frequent algorithms used in the literature for PCa classification are logistic regression (22%) and convolutional neural networks (CNNs) (22%). The median AUC was 0.79 (interquartile range: 0.77–0.87). No significant effect of number of included patients, image sequences, or reference standard on the reported performance was found. Three studies described an external validation and none of the papers described a validation in a prospective clinical trial. Conclusions: To unlock the promising potential of machine and deep learning approaches, validation studies and clinical prospective studies should be performed with an established protocol to assess the added value in decision-making.
- Published
- 2020
- Full Text
- View/download PDF
10. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
- Author
-
Osses, D.F. (Daniël), Drost, F.J.H. (Frank-Jan), Verbeek, J.F.M. (Jan), Luiting, H.B. (Henk B.), Leenders, G.J.H.L. (Geert), Bangma, C.H. (Chris), Krestin, G.P. (Gabriel), Roobol-Bouts, M.J. (Monique), Schoots, I.G. (Ivo), Osses, D.F. (Daniël), Drost, F.J.H. (Frank-Jan), Verbeek, J.F.M. (Jan), Luiting, H.B. (Henk B.), Leenders, G.J.H.L. (Geert), Bangma, C.H. (Chris), Krestin, G.P. (Gabriel), Roobol-Bouts, M.J. (Monique), and Schoots, I.G. (Ivo)
- Abstract
Objectives: To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with low-risk prostate cancer (PCa) at 1-year of active surveillance (AS). Patients and Methods: We retrospectively included 111 consecutive men with low-risk (International Society of Urological Pathology [ISUP] Grade 1) PCa, who received protocolled repeat MRI with or without TBx and repeat SBx at 1-year of AS. TBx was performed in Prostate Imaging-Reporting and Data System (PI-RADS) score ≥3 lesions (MRI-positive men). Upgrading defined as ISUP Grade ≥2 PCa (I), Grade ≥2 with cribriform growth/intraductal carcinoma PCa (II), and Grade ≥3 PCa (III) was investigated. Upgrading detected by TBx only (not by SBx) and SBx only (not by TBx) was investigated in MRI-positive and -negative men, and related to radiological progression on MRI (Prostate Cancer Radiological Estimation of Change in Sequential Evaluation [PRECISE] score). Results: Overall upgrading (I) was 32% (35/111). Upgrading in MRI-positive and -negative men was 48% (30/63) and 10% (5/48) (P < 0.001), respectively. In MRI-positive men, there was upgrading in 23% (seven of 30) by TBx only and in 33% (10/30) by SBx only. Radiological progression (PRECISE score 4–5) in MRI-positive men was seen in 27% (17/63). Upgrading (I) occurred in 41% (seven of 17) of these MRI-positive men, while this was 50% (23/46) in MRI-positive men without radiological progression (PRECISE score 1–3) (P = 0.534). Overall upgrading (II) was 15% (17/111). Upgrading in MRI-positive and -negative men was 22% (14/63) and 6% (three of 48) (P = 0.021), respectively. In MRI-positive men, there was upgrading in three of 14 by TBx only and in seven of 14 by SBx only. Overall upgrading (III) occurred in 5% (five of 111). Upgrading in MRI-positive and -negative men was 6% (four of 63) and 2% (one of 48) (P = 0.283), respectively. In MRI-positive men, there was upgradin
- Published
- 2020
- Full Text
- View/download PDF
11. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training
- Author
-
Rooij, M. (Maarten) de, Israël, B. (Bas), Tummers, M. (Marcia), Ahmed, H.U. (Hashim), Barrett, T. (Tristan), Giganti, F. (Francesco), Hamm, B. (Bernd), Løgager, V. (Vibeke), Padhani, A. (Anwar), Panebianco, V. (Valeria), Puech, P. (Philippe), Richenberg, J. (Jonathan), Rouvière, O. (Olivier), Salomon, G. (Georg), Schoots, I.G. (Ivo), Veltman, J., Villeirs, G. (Geert), Walz, J. (Jochen), Barentsz, J. (Jelle), Rooij, M. (Maarten) de, Israël, B. (Bas), Tummers, M. (Marcia), Ahmed, H.U. (Hashim), Barrett, T. (Tristan), Giganti, F. (Francesco), Hamm, B. (Bernd), Løgager, V. (Vibeke), Padhani, A. (Anwar), Panebianco, V. (Valeria), Puech, P. (Philippe), Richenberg, J. (Jonathan), Rouvière, O. (Olivier), Salomon, G. (Georg), Schoots, I.G. (Ivo), Veltman, J., Villeirs, G. (Geert), Walz, J. (Jochen), and Barentsz, J. (Jelle)
- Abstract
Objectives: This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prerequisites for image quality. Methods: A total of 44 leading urologists and urogenital radiologists who are experts in prostate cancer imaging from the European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI) participated in a Delphi consensus process. Panellists completed two rounds of questionnaires with 55 items under three headings: image quality assessment, interpretation and reporting, and radiologists’ experience plus training centres. Of 55 questions, 31 were rated for agreement on a 9-point scale, and 24 were multiple-choice or open. For agreement items, there was consensus agreement with an agreement ≥ 70% (score 7–9) and disag
- Published
- 2020
- Full Text
- View/download PDF
12. The primacy of multiparametric MRI in men with suspected prostate cancer
- Author
-
Richenberg, J., Logager, V., Panebianco, V., Rouviere, O, Villeirs, G., Schoots, I.G. (Ivo), Richenberg, J., Logager, V., Panebianco, V., Rouviere, O, Villeirs, G., and Schoots, I.G. (Ivo)
- Abstract
Background Multiparametric MRI (mpMRI) became recognised in investigating those with suspected prostate cancer between 2010 and 2012; in the USA, the preventative task force moratorium on PSA screening was a strong catalyst. In a few short years, it has been adopted into daily urological and oncological practice. The pace of clinical uptake, born along by countless papers proclaiming high accuracy in detecting clinically significant prostate cancer, has sparked much debate about the timing of mpMRI within the traditional biopsy-driven clinical pathways. There are strongly held opposing views on using mpMRI as a triage test regarding the need for biopsy and/or guiding the biopsy pattern. Objective To review the evidence base and present a position paper on the role of mpMRI in the diagnosis and management of prostate cancer. Methods A subgroup of experts from the ESUR Prostate MRI Working Group conducted literature review and face to face and electronic exchanges to draw up a position statement. Results This paper considers diagnostic strategies for clinically significant prostate cancer; current national and international guidance; the impact of pre-biopsy mpMRI in detection of clinically significant and clinically insignificant neoplasms; the impact of pre-biopsy mpMRI on biopsy strategies and targeting; the notion of mpMRI within a wider risk evaluation on a patient by patient basis; the problems that beset mpMRI including inter-observer variability. Conclusions The paper concludes with a set of suggestions for using mpMRI to influence who to biopsy and who not to biopsy at diagnosis.
- Published
- 2019
- Full Text
- View/download PDF
13. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility
- Author
-
van der Leest, M., Israel, B., Cornel, E.B. (Erik), Zamecnik, P., Schoots, I.G. (Ivo), van der Lelij, H., Padhani, A.R., Rovers, M., van Oort, I., Sedelaar, M, Hulsbergen-van de Kaa, C.A. (Christina), Hannink, G., Veltman, J., Barentsz, J. (Jelle), van der Leest, M., Israel, B., Cornel, E.B. (Erik), Zamecnik, P., Schoots, I.G. (Ivo), van der Lelij, H., Padhani, A.R., Rovers, M., van Oort, I., Sedelaar, M, Hulsbergen-van de Kaa, C.A. (Christina), Hannink, G., Veltman, J., and Barentsz, J. (Jelle)
- Abstract
Background: To make magnetic resonance imaging (MRI) more accessible to men at risk of high-grade prostate cancer (PCa), there is a need for quicker, simpler, and less costly MRI protocols. Objective: To compare the diagnostic performance of monoplanar (“fast” biparametric MRI [bp-MRI]) and triplanar noncontrast bp-MRI with that of the current contrast-enhanced multiparametric MRI (mp-MRI) in the detection of high-grade PCa in biopsy-naïve men. Design, setting, and participants: A prospective, multireader, head-to-head study included 626 biopsy-naïve men, between February 2015 and February 2018. Intervention: Men underwent prebiopsy contrast-enhanced mp-MRI. Prior to biopsy, two blinded expert readers subsequently assessed “fast” bp-MRI, bp-MRI, and mp-MRI. Thereafter, systematic transrectal ultrasound-guided biopsies (SBs) were performed. Men with suspicious mp-MRI (Prostate Imaging Reporting and Data System 3–5 lesions) also underwent MR-in-bore biopsy (MRGB). Outcome measurements and statistical analysis: Primary outcome was the diagnostic performance of each protocol for the detection of high-grade PCa. Secondary outcomes included the difference in biopsy avoidance, detection of low-grade PCa, acquisition times, decision curve analyses, inter-reader agreement, and direct costs. Results from combined MRGB and SB were used as the reference standard. High-grade PCa was defined as grade 2. Results and limitations: Sensitivity for high-grade PCa for all protocols was 95% (180/ 190; 95% confidence interval [CI]: 91–97%). Specificity was 65% (285/436; 95% CI: 61–70%) for “fast” bp-MRI and 69% (299/436; 95% CI: 64–73%) for bp-MRI and mp-MRI. With fast bp-MRI, 0.96% (6/626) more low-grade PCa was detected. Biopsy could be avoided in 47% for the fast bp-MRI and in 49% for the bp-MRI and mp-MRI protocols. Fast bp-MRI and bp-MRI can be performed in 8 and 13 min, respectively, instead of 16 m
- Published
- 2019
- Full Text
- View/download PDF
14. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
- Author
-
Schoots, I.G. (Ivo), Padhani, A. (Anwar), Schoots, I.G. (Ivo), and Padhani, A. (Anwar)
- Abstract
Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, either by clinical judgment and PSA testing, or using multivariate risk prediction tools. The use of multivariable risk prediction tools can significantly reduce unnecessary systematic biopsies, without compromising the detection of clinically significant disease. Increasingly multi-parametric magnetic resonance imaging (MRI) is performed, not only in men with a persistent suspicion of prostate cancer after prior negative systematic biopsy, but also at initial screening before the first biopsy. The combination of MRI and multivariate risk prediction tools could potentially enhance prostate cancer diagnosis using multivariate MRI incorporated risk-based models to decide on the need for prostate MRI, but also using MRI results to adjusted risk-based models, and to guide MRI-directed biopsies. In this review, we discuss the diagnostic work-up for clinically significant prostate cancer, where the combination of MRI and multivariate risk prediction tools is integrated, and how together they can contribute to personalized diagnosis.
- Published
- 2019
- Full Text
- View/download PDF
15. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens
- Author
-
Hollemans, E. (Eva), Verhoef, E.I. (Esther), Bangma, C.H. (Chris), Schoots, I.G. (Ivo), Rietbergen, J.B. (John), Helleman, J. (Jozien), Roobol-Bouts, M.J. (Monique), Leenders, G.J.H.L. (Geert), Hollemans, E. (Eva), Verhoef, E.I. (Esther), Bangma, C.H. (Chris), Schoots, I.G. (Ivo), Rietbergen, J.B. (John), Helleman, J. (Jozien), Roobol-Bouts, M.J. (Monique), and Leenders, G.J.H.L. (Geert)
- Abstract
Aims: Invasive cribriform and/or intraductal carcinoma have been identified as independent adverse parameters for prostate cancer outcome. Little is known on biopsy undersampling of cribriform architecture. Our aim was to determine the extent of cribriform architecture undersampling and to find predictive factors for identifying false cribriform-negative cases. Methods and results: We reviewed 186 matched prostate biopsies and radical prostatectomy specimens. Of 97 biopsy grade group 2 (Gleason score 3 + 4 = 7) patients, 22 (23%) had true cribriform-negative (TN), 39 (40%) false-negative (FN) and 36 (37%) true-positive (TP) biopsies. Patients with FN biopsies had higher, although not statistically significant (P = 0.06), median PSA levels than patients with TP biopsies (12 versus 8 ng/ml). A PI-RADS 5 lesion was present in nine of 16 (54%) FN and three of 11 (27%) TN biopsies (P = 0.05). Positive biopsy rate (P = 0.47), percentage Gleason pattern 4 (P = 0.55) and glomeruloid architecture (P = 1.0) were not different. Logistic regression identified PSA as an independent pre
- Published
- 2019
- Full Text
- View/download PDF
16. Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
- Author
-
Osses, D.F. (Daniël), Roobol-Bouts, M.J. (Monique), Schoots, I.G. (Ivo), Osses, D.F. (Daniël), Roobol-Bouts, M.J. (Monique), and Schoots, I.G. (Ivo)
- Abstract
This review discusses the most recent evidence for currently available risk stratification tools in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic strategies that combine these tools. Novel blood biomarkers, such as the Prostate Health Index (PHI) and 4Kscore, show similar ability to predict csPCa. Prostate cancer antigen 3 (PCA3) is a urinary biomarker that has inferior prediction of csPCa compared to PHI, but may be combined with other markers like TMPRSS2-ERG to improve its performance. Original risk calculators (RCs) have the advantage of incorporating easy to retrieve clinical variables and being freely accessible as a web tool/mobile application. RCs perform similarly well as most novel biomarkers. New promising risk models including novel (genetic) markers are the SelectMDx and Stockholm-3 model (S3M). Prostate magnetic resonance imaging (MRI) has evolved as an appealing tool in the diagnostic arsenal with even stratifying abilities, including in the initial biopsy setting. Merging biomarkers, RCs and MRI results in higher performances than their use as standalone tests. In the current era of prostate MRI, the way forward seems to be multivariable risk assessment based on blood and clinical parameters, potentially extended with information from urine samples, as a triaging test for the selection of candidates for MRI and biopsy
- Published
- 2019
- Full Text
- View/download PDF
17. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands
- Author
-
Boer, G.M. (Geertje) de, Hofhuis, W., Reesink-Peters, N., Ewing-Graham, P.C., Schoots, I.G. (Ivo), Beltman, J.J., Piek, J.M.J., Baalbergen, A., Kooi, G.S. (Sjarlot), van Haaften, A., van Huisseling, H., Haans, L., Dorman, M., Beekhuizen, H.J. (Heleen) van, Boer, G.M. (Geertje) de, Hofhuis, W., Reesink-Peters, N., Ewing-Graham, P.C., Schoots, I.G. (Ivo), Beltman, J.J., Piek, J.M.J., Baalbergen, A., Kooi, G.S. (Sjarlot), van Haaften, A., van Huisseling, H., Haans, L., Dorman, M., and Beekhuizen, H.J. (Heleen) van
- Abstract
Background: The most important goal for survival benefit of advanced stage ovarian cancer is to surgically remove all visible tumour, because complete cytoreductive surgery (CCS) has been shown to be associated with prolonged survival. In a remarkable number of women, CCS is very challenging. Especially in women with many small metastases on the peritoneum and intestinal surface, conventional CCS with electrosurgery is not able to be “complete” in removing safely all visible tumour. In this randomized controlled trail (RCT) we investigate whether the use of the PlasmaJet Surgical Device increases the rate of CCS, and whether this indeed leads to a longer progression free and overall survival. The main research question is: does the use of the PlasmaJet Surgical Device in surgery for advanced stage ovarian cancer result in an increased number of complete cytoreductive surgeries when compared with conventional surgical techniques. Secondary study objectives are: 30-day morbidity, duration of surgery, blood loss, length of hospitalisation, Quality of Life, disease-free survival, overall survival, percentage colostomy, cost-effectiveness. Methods: The study design is a multicentre single-blinded superiority RCT in two university and nine non-university hospitals in The Netherlands. Three hundred and thirty women undergoing cytoreductive surgery for advanced stage ovarian carcinoma (FIGO Stage IIIB-IV) will be randomized into two arms: use of the PlasmaJet (intervention group) versus the use of standard surgical instruments combined with electrocoagulation (control group). The primary outcome is the rate of complete cytoreductive surgery in both groups. Secondary study objectives are: 30-day morbidity, duration of surgery, blood loss, length of hospitalisation, Quality of Life, disease-free survival, overall survival, percentage colostomy, cost-effectiveness. Quality of life will be evaluated using validated questionnaires at baseline, at 1 and 6 months after surgery and
- Published
- 2019
- Full Text
- View/download PDF
18. From PROMIS to PRO-MRI in primary prostate cancer diagnosis
- Author
-
Schoots, I.G. (Ivo), Roobol-Bouts, M.J. (Monique), Schoots, I.G. (Ivo), and Roobol-Bouts, M.J. (Monique)
- Abstract
In the emerging field of MRI in prostate cancer (PCa) diagnosis, it has become clear that targeted biopsy with MRI guidance has additional value over systematic transrectal ultrasound-guided biopsies (TRUS-Bx) alone. The targeted biopsy approach driven by a positive MRI increases the diagnostic yield of high-grade [Gleason score (GS) ≥3+4] or clinically significant (cs) PCa, while concomitantly reducing the number of biopsy cores and the detection of low-grade PCa (GS 3+3) (1-3). Consequently, the question arises what the diagnostic accuracy of MRI (with or without targeted biopsies) in current clinical practice would be?
- Published
- 2017
- Full Text
- View/download PDF
19. From PROMIS to PRO-MRI in primary prostate cancer diagnosis
- Author
-
Schoots, I.G. (Ivo), Roobol-Bouts, M.J. (Monique), Schoots, I.G. (Ivo), and Roobol-Bouts, M.J. (Monique)
- Abstract
In the emerging field of MRI in prostate cancer (PCa) diagnosis, it has become clear that targeted biopsy with MRI guidance has additional value over systematic transrectal ultrasound-guided biopsies (TRUS-Bx) alone. The targeted biopsy approach driven by a positive MRI increases the diagnostic yield of high-grade [Gleason score (GS) ≥3+4] or clinically significant (cs) PCa, while concomitantly reducing the number of biopsy cores and the detection of low-grade PCa (GS 3+3) (1-3). Consequently, the question arises what the diagnostic accuracy of MRI (with or without targeted biopsies) in current clinical practice would be?
- Published
- 2017
- Full Text
- View/download PDF
20. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- Author
-
Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Cornford, P. (Philip), Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), and Cornford, P. (Philip)
- Abstract
Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. Evidence synthesis: . BRCA2 mutations have been added as risk factors for early and aggressive disease. In addition to the Gleason score, the five-tier 2014 International Society of Urological Pathology grading system should now be provided. Systematic screening is still not recommended. Instead, an individual risk-adapted strategy following a detailed discussion and taking into account the patient's wishes and life expectancy must be considered. An early prostate-specific antigen test, the use of a risk calculator, or one of the promising biomarker tools are being investigated and might be able to limit the overdetection of insignificant PCa. Breaking the link between diagnosis and treatment may lower the overtreatment risk. Multiparametric magnetic resonance imaging
- Published
- 2017
- Full Text
- View/download PDF
21. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy?
- Author
-
Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), Rouvière, O. (Olivier), Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), and Rouvière, O. (Olivier)
- Abstract
Context: It remains unclear whether patients with a suspicion of prostate cancer (PCa) and negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate biopsy. Objective: To systematically review the literature assessing the negative predictive value (NPV) of mpMRI in patients with a suspicion of PCa. Evidence acquisition: The Embase, Medline, and Cochrane databases were searched up to February 2016. Studies reporting prebiopsy mpMRI results using transrectal or transperineal biopsy as a reference standard were included. We further selected for meta-analysis studies with at least 10-core biopsies as the reference standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, positive mpMRI defined as a Prostate Imaging Reporting Data System/Likert score of ≥3/5 or ≥4/5, and results reported at patient level for the detection of overall PCa or clinically significant PCa (csPCa) defined as Gleason ≥7 cancer. Evidence synthesis: A total of 48 studies (9613 patients) were eligible for inclusion. At patient level, the median prevalence was 50.4% (interquartile range [IQR], 36.4-57.7%) for overall cancer and 32.9% (IQR, 28.1-37.2%) for csPCa. The median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for overall cancer and 88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased when cancer prevalence increased, for overall cancer (r = -0.64, p <. 0.0001) and csPCa (r = -0.75, p = 0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. Seven reported results for overall PCa. When the overall PCa prevalence increased from 30% to 60%, the combined NPV estimates decreased from 88% (95% confidence interval [95% CI], 77-99%) to 67% (95% CI, 56-79%) for a cut-off score of 3/5. Only one study selected for meta-analysis reported results for Gleason ≥7 cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off score of ≥3/5 was 87.9%. Conclusions: The NPV of mpMRI varied greatly depending on study des
- Published
- 2017
- Full Text
- View/download PDF
22. Omission of systematic transrectal ultrasound guided biopsy from the MRI targeted approach in men with previous negative prostate biopsy might still be premature
- Author
-
Schoots, I.G. (Ivo) and Schoots, I.G. (Ivo)
- Published
- 2016
- Full Text
- View/download PDF
23. The Bosniak classification for renal cysts: time for another change?
- Author
-
Lamers, R.E.D. (Romy E.D.), Zaccai, K. (Kèren), Schoots, I.G. (Ivo), Verhagen, P.C.M.S. (Paul), Lamers, R.E.D. (Romy E.D.), Zaccai, K. (Kèren), Schoots, I.G. (Ivo), and Verhagen, P.C.M.S. (Paul)
- Abstract
The Bosniak renal cyst classification was introduced in 1986. This classification was based on computed tomography (CT). In the course of years several adjustments were proposed. The current classification contains five categories: I, II, IIF, III and IV. Categorie I and II lesions are assumed benign and do not require further treatment. A IIF lesion is possibly benign and surveillance is advised. Lesions in categorie III and IV are suspect for malignancy and treatment is advised. Only few studies reported interobserver variability which was high. More recent studies incorporate MRI and CEUS in the Bosniak classification system which further impedes interpretation. MRI and CEUS are more sensitive to detect enhancement in a lesion and may upgrade a lesion compared to CT. In Bosniak III cysts the risk for malignancy is approximately 50 %. If malignant, histology usually shows cystic renal cell carcinoma which has been reported to follow a more favourable course compared to solid tumours. In our opinion there are good arguments to imply surveillance for Bosniak III cysts < 4 cm, similar to the approach of IIF lesions. The risk for tumour progression is very small while overtreatment is reduced. It will be important to improve the definition of a category IV lesion.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.